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for the purpose of achieving intoxication. Inhalants are among the most common and pernicious forms of
substance use and the least studied of the major drugs. Diagnosis of inhalant dependence, according to
the DSM-IV [Weintraub E, Gandhi D, Robinson C. Medical complications due to mothball abuse. South
Med J 2000;93:427–9] excludes inhalant withdrawal symptoms, as expert opinion has suggested that
an inhalant withdrawal syndrome is neither common nor clinically significant. This article draws from
multiple sources of data to suggest that withdrawal symptoms can be part of inhalant dependence and
are clinically significant. This hypothesis needs rigorous evaluation to ensure the diagnostic validity of
inhalant use disorders.
 2009 Elsevier Ltd. All rights reserved.Introduction
Inhalant use is the intentional inhalation of vapors from com-
mercial products or specific chemical agents for the purpose of
achieving intoxication [1]. Commonly abused products include
gasoline, glue, paint thinner, nail polish, nail polish remover, and
spray paint [2]. Numerous specific chemicals may be inhaled
including acetone, benzene, butanone, n-hexane, and toluene,
although varied mixtures of chemicals are found in many abused
products [3].
Inhalants are among the most common and pernicious forms of
substance use [4,5] and the least studied of the major drugs [6,7].
Inhalant use is associated with harmful outcomes that rival or
exceed those characteristic of other drugs of abuse [8,9]. They dis-
proportionately afflict vulnerable subpopulations including the
poor, select minority groups, the mentally ill, and persons involved
with the juvenile and criminal justice systems [10,11]. Inhalants
can lead to ‘‘sudden sniffing death” and serious accidents
[12–14]. Recent research found that nearly 20% of adults who used
inhalants met lifetime criteria for inhalant abuse or dependence
[15]. Recent survey evidence also shows widespread use in the
adolescent population – that is, approximately 16.1% of 8th graders
reported inhalant use, which is slightly higher than the rate of
marijuana use among this group (15.7%) [16]. Other survey results
show that over one-half million youth aged 12–17 years reported
past-year inhalant use [17].ll rights reserved.
.
Very little research on inhalant use disorders exists [18]. The
general absence of knowledge is reflected in minimal description
of inhalant use disorders in the Diagnostic and Statistical Manual,
4th Edition (DSM-IV) [18] vis-à-vis prevalence, course, subtypes,
comorbid medical and mental health conditions, and specific age,
gender, and sociodemographic features. Moreover, recent findings
have raised questions about the reliability and validity of the DSM-
IV criteria for inhalant use disorders [19]. This underscores the
need for further research on the dimensionality of problematic
inhalant use [20] and key signs and symptoms of inhalant use dis-
orders, including tolerance and withdrawal [21–23].
Inhalant use disorders
Thirteen different classes of psychoactive substances for which
abuse or dependence diagnoses exist are defined by DSM-IV [18].
Inhalants represent a distinct class of substances and include both
abuse and dependence diagnoses.
Inhalant abuse
Inhalant abuse is defined using the same set of criteria used for
all other substance use disorders – that is, having one or more mal-
adaptive patterns of use that results in clinically significant impair-
ment or distress, including (1) recurrent failure to fulfill major role
obligations; (2) recurrent use in physically hazardous situations;
(3) recurrent substance-related legal problems; and (4) continued
use despite persistent or recurrent social or interpersonal problems
due to use [18].
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Whereas inhalant abuse is defined using the same criteria set
used for abuse of other substances, inhalant dependence is defined
using a slightly different criteria set than that used for other sub-
stances. Specifically, a diagnosis of inhalant dependence requires
that three of six dependence criteria be met, whereas other sub-
stances with a withdrawal syndrome require that three of seven
criteria be met. The six diagnostic criteria for inhalant dependence
include: (1) tolerance; (2) substance (inhalant) taken in larger
amounts over longer period than intended; (3) a persistent desire
or unsuccessful efforts to cut down or control substance (inhalant)
use; (4) a great deal of time spent in activities necessary to obtain
substance (inhalant) use the substance (inhalant), or recover from
its effects; (5) important social, occupational, or recreational activ-
ities given up or reduced due to substance (inhalant) use; and (6)
substance (inhalant) use is continued despite knowledge of ad-
verse physiological or psychological effects.
Five classes of substances for which a dependence disorder ex-
ists do not have a diagnosable withdrawal disorder, including
inhalants. In the clinical description of inhalant dependence, the
DSM-IV states, ‘‘A possible mild withdrawal syndrome has been re-
ported but has not been well documented and does not appear to
be clinically significant” [18] (p. 258).Hypothesis
Inhalant dependence, as defined by the DSM-IV [18], can in-
clude clinically significant withdrawal symptoms that are charac-
teristic of other forms of substance dependence.Evaluation
The decision to exclude inhalant withdrawal symptoms from the
DSM-IV diagnostic criteria set is based on expert opinion and does
not take into account the currently available evidence. For example,
a detailed case study of a 21-year-old male reported that he experi-
enced ‘‘increased irritability, anxiety, with poor attention and
concentration” and ‘‘craving” [24] (p. 770) between sessions of
inhalant use. Another case report described a 14-year-old boy with
‘‘experiences of intense craving [that] interrupted his everyday
routine in school and at home” [21] (p. 679). The boy’s clinically dis-
tressing withdrawal symptoms, both psychological and physiologi-
cal, persisted for seven days during a hospitalization. The authors of
this case report argued that inhalant withdrawal symptoms can be
clinically significant among heavy inhalant users, resembling the
nature and severity of alcohol withdrawal symptoms.
Ridenour and colleagues [19] reported that inhalant withdrawal
was the second most common inhalant dependence criterion
among a sample of adolescent inhalant users. A total of 11.1% re-
ported headaches, nausea or vomiting, hallucinations, runny eyes
or nose, craving, fast heart beat, depressed mood, and anxiety dur-
ing withdrawal from inhalants. Other researchers have described
an inhalant withdrawal syndrome based on small sample studies,
especially those with in-depth comparisons of the phenomenology
of inhalant experiences [25]. Comparative studies of clinical pre-
sentations for various substances showed inhalants to produce
withdrawal symptoms that included restlessness, inattentiveness,
anxiety, insomnia, and high levels of craving [26,27].
In addition to studies of human subjects, prior research involv-
ing animals in carefully controlled conditions have demonstrated
symptoms of physical dependence on and withdrawal from inhal-
ants. For example, in a classic study by Evans and Balster [28], mice
were exposed to 1,1,1 – Trichloroethane (TCE), a widely abused
solvent. Cessation of 4 days of continuous inhalation of this sub-stance resulted in a withdrawal syndrome characterized by con-
vulsions. The convulsions diminished 30–60 min following re-
exposure to TCE vapor or toluene.Conclusion
A stronger knowledge base about inhalant-related symptoms
is needed to ensure accurate DSM-IV definitions of inhalant use
disorders. This article reviewed clinical, survey and animal stud-
ies that imply clinically significant withdrawal symptoms are
part of inhalant dependence disorder, and an important step in
future research is testing this hypothesis. Moreover, this line of
hypothesis testing can lead to a better understanding of the clin-
ical course of inhalant use disorders, which will greatly aid in
developing evidence-based treatments and aiding treatment
selection. This is particularly important given that no evi-
denced-based treatments for inhalant use disorders exist. With-
out this knowledge, inhalant users may be at risk of being
misdiagnosed and face restricted access to treatment, and inter-
ventions for inhalant use disorders will not adequately address
the full range of clinical needs.
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